ATE415173T1 - Pan dr-bindeproteinen zur erhöhung der immunantwort - Google Patents

Pan dr-bindeproteinen zur erhöhung der immunantwort

Info

Publication number
ATE415173T1
ATE415173T1 AT94929801T AT94929801T ATE415173T1 AT E415173 T1 ATE415173 T1 AT E415173T1 AT 94929801 T AT94929801 T AT 94929801T AT 94929801 T AT94929801 T AT 94929801T AT E415173 T1 ATE415173 T1 AT E415173T1
Authority
AT
Austria
Prior art keywords
peptides
pan
increase
immune response
binding proteins
Prior art date
Application number
AT94929801T
Other languages
English (en)
Inventor
Alessandro Sette
Federico C A Gaeta
Howard M Grey
John Sidney
Jerrery L Alexander
Original Assignee
Pharmexa Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmexa Inc filed Critical Pharmexa Inc
Application granted granted Critical
Publication of ATE415173T1 publication Critical patent/ATE415173T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT94929801T 1993-09-14 1994-09-14 Pan dr-bindeproteinen zur erhöhung der immunantwort ATE415173T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12110193A 1993-09-14 1993-09-14

Publications (1)

Publication Number Publication Date
ATE415173T1 true ATE415173T1 (de) 2008-12-15

Family

ID=22394559

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94929801T ATE415173T1 (de) 1993-09-14 1994-09-14 Pan dr-bindeproteinen zur erhöhung der immunantwort

Country Status (11)

Country Link
US (2) US5736142A (de)
EP (1) EP0735893B1 (de)
JP (1) JP3926839B2 (de)
CN (1) CN1135181A (de)
AT (1) ATE415173T1 (de)
AU (1) AU698962B2 (de)
DE (1) DE69435171D1 (de)
DK (1) DK0735893T3 (de)
ES (1) ES2318848T3 (de)
PT (1) PT735893E (de)
WO (1) WO1995007707A1 (de)

Families Citing this family (206)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7611713B2 (en) * 1993-03-05 2009-11-03 Pharmexa Inc. Inducing cellular immune responses to hepatitis B virus using peptide compositions
US7252829B1 (en) * 1998-06-17 2007-08-07 Idm Pharma, Inc. HLA binding peptides and their uses
US20110097352A9 (en) * 1992-01-29 2011-04-28 Pharmexa Inc. Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compositions
US9266930B1 (en) 1993-03-05 2016-02-23 Epimmune Inc. Inducing cellular immune responses to Plasmodium falciparum using peptide and nucleic acid compositions
ES2318848T3 (es) 1993-09-14 2009-05-01 Pharmexa Inc. Peptidos que se unen a pan dr para potenciar la respuesta inmunitaria.
US6413935B1 (en) * 1993-09-14 2002-07-02 Epimmune Inc. Induction of immune response against desired determinants
US20050049197A1 (en) * 1993-09-14 2005-03-03 Epimmune Inc. Induction of immune response against desired determinants
WO1996010415A1 (en) * 1994-09-30 1996-04-11 Anergen, Inc. Preparation of mhc-peptide complexes
GB9509844D0 (en) * 1995-05-16 1995-07-12 Cancer Res Campaign Tech Screening for inhibitors of TCR-MHC interactions
JP4063879B2 (ja) * 1996-01-24 2008-03-19 エピミューン インコーポレイテッド 所望の決定基に対する免疫応答の誘導
GB9702377D0 (en) * 1996-02-23 1997-03-26 Zeneca Ltd Peptide derivatives
US20040171028A1 (en) * 1996-06-06 2004-09-02 Baker Brenda F. Phosphorous-linked oligomeric compounds and their use in gene modulation
CA2252417A1 (en) 1996-06-07 1997-12-11 Zeneca Limited Peptide derivatives
JP4156671B2 (ja) * 1996-06-11 2008-09-24 ノーザン シドニー アンド セントラル コースト エリア ヘルス サービス Ｔ細胞抗原受容体ペプチド
GB9621836D0 (en) 1996-10-19 1996-12-11 Zeneca Ltd Peptide compounds
US6562345B1 (en) 1996-11-12 2003-05-13 City Of Hope Immuno-reactive peptide CTL epitopes of human cytomegalovirus
GB9624562D0 (en) 1996-11-27 1997-01-15 Zeneca Ltd Peptide derivatives
US6413517B1 (en) 1997-01-23 2002-07-02 Epimmune, Inc. Identification of broadly reactive DR restricted epitopes
US20080050367A1 (en) * 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US6743427B1 (en) 1997-12-02 2004-06-01 Neuralab Limited Prevention and treatment of amyloidogenic disease
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
US7179892B2 (en) * 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6923964B1 (en) 1997-12-02 2005-08-02 Neuralab Limited Active immunization of AScr for prion disorders
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6710226B1 (en) 1997-12-02 2004-03-23 Neuralab Limited Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics
US7790856B2 (en) * 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
US20050059802A1 (en) * 1998-04-07 2005-03-17 Neuralab Ltd Prevention and treatment of amyloidogenic disease
ES2371432T3 (es) * 1998-05-13 2012-01-02 Epimmune Inc. Vectores de expresión para estimular una respuesta inmune y procedimientos de uso de los mismos.
AU4078599A (en) 1998-05-13 1999-11-29 Epimmune, Inc. Expression vectors for stimulating an immune response and methods of using the same
US20030147882A1 (en) * 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
WO1999065522A1 (en) 1998-06-17 1999-12-23 Epimmune Inc. Hla binding peptides and their uses
JP2003521448A (ja) 1998-07-23 2003-07-15 ザ・プレジデント・アンド・フェローズ・オブ・ハーバード・カレッジ 合成ペプチドおよび自己免疫疾患治療のための使用方法
US6800730B1 (en) * 1998-10-02 2004-10-05 Ludwig Institute For Cancer Research Isolated peptides which bind to MHC class II molecules, and uses thereof
CZ20011049A3 (cs) 1998-10-05 2002-08-14 Pharmexa A/S Imunogenní kompozice a způsob selekce imunogenního analogu
ID28387A (id) * 1998-10-05 2001-05-17 M & E Biotech As Metoda baru untuk vaksinasi terapeutik
HUP0200958A3 (en) 1999-04-23 2004-11-29 Pharmexa As Method for down-regulating il5 activity
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
UA81216C2 (en) * 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
EP1200109A4 (de) * 1999-07-19 2005-06-15 Epimmune Inc Verwendung von peptid-nukleinsäureverbindungen zur auslösung zellulärer immunantworten gegen hepatitis c
HUP0201861A3 (en) 1999-07-20 2004-07-28 Pharmexa As Method for down-regulating gdf-8 activity
AU1075001A (en) * 1999-10-05 2001-05-10 Epimmune, Inc. Inducing cellular immune responses to human immunodeficiency virus-1 using peptide and nucleic acid compositions
AU1661201A (en) * 1999-11-18 2001-05-30 Epimmune, Inc. Heteroclitic analogs and related methods
PT1234031T (pt) 1999-11-30 2017-06-26 Mayo Foundation B7-h1, uma nova molécula imunoregulatória
US7026443B1 (en) 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
JP2003521245A (ja) * 1999-12-21 2003-07-15 エピミューン， インコーポレイテッド ペプチドおよび核酸組成物を使用する、前立腺癌抗原に対する細胞性免疫応答の誘導
US7462354B2 (en) * 1999-12-28 2008-12-09 Pharmexa Inc. Method and system for optimizing minigenes and peptides encoded thereby
BR0108566A (pt) * 2000-02-21 2002-11-19 Pharmexa As Método para a regulação negativa in vivo de proteìna amilóide em um animal, incluindo um ser humano e para o tratamento e/ou prevenção e/ou melhora da doença de alzheimer ou outras doenças e condições cartacterizadas por depósitos de amilóide, análogo de um polipeptìdeo amiloidogênico,composição imunogênica, fragmento de ácido nucleico, vetor, célula transformada, composição para induzir a produção de anticorpos contra um polipeptìdeo amiloidogênico, linhagem celular estável, métodos para a preparação de uma célula, para a identificação de um polipeptìdeo amiloidogênico modificado, e para preparação de uma composição imunogênica, uso de um polipeptìdeo amiloidogênico ou de uma subsequência do mesmo, e, uso de um análogo de um polipeptìdeo amiloidogênico
AU783144B2 (en) * 2000-02-21 2005-09-29 H. Lundbeck A/S Novel method for down-regulation of amyloid
US7030219B2 (en) 2000-04-28 2006-04-18 Johns Hopkins University B7-DC, Dendritic cell co-stimulatory molecules
EP1652856A1 (de) * 2000-08-09 2006-05-03 The Regents of The University of California San Diego Stressproteine-abgeleitete Peptide und Verfahren zu deren Verwendung
US6989146B2 (en) * 2000-08-09 2006-01-24 The Regents Of The University Of California Stress proteins and peptides and methods of use thereof
US6664230B1 (en) * 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US7199102B2 (en) 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
PT1313850E (pt) 2000-08-28 2008-11-18 Agensys Inc Ácido nucleico e proteína correspondente denominados 85p1b3 úteis no tratamento e na detecção de cancro
ATE536187T1 (de) 2000-10-19 2011-12-15 Epimmune Inc Hla-klasse-i- und -klasse-ii-bindende peptide und ihre verwendungen
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
TWI255272B (en) * 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US20040121946A9 (en) * 2000-12-11 2004-06-24 John Fikes Inducing cellular immune responses to her2/neu using peptide and nucleic acid compositions
US7097837B2 (en) 2001-02-19 2006-08-29 Pharmexa A/S Synthetic vaccine agents
US6924358B2 (en) 2001-03-05 2005-08-02 Agensys, Inc. 121P1F1: a tissue specific protein highly expressed in various cancers
US7271240B2 (en) 2001-03-14 2007-09-18 Agensys, Inc. 125P5C8: a tissue specific protein highly expressed in various cancers
EP2280030A3 (de) 2001-04-10 2011-06-15 Agensys, Inc. Nukleinsäuren und zugehörige Proteine für die Behandlung und den Nachweis von Krebs
US20030191073A1 (en) 2001-11-07 2003-10-09 Challita-Eid Pia M. Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer
EP1395276A4 (de) * 2001-05-15 2004-12-29 Ludwig Inst Cancer Res Struktur-modifizierte peptide und ihre verwendungen
MY144532A (en) * 2001-08-20 2011-09-30 Lundbeck & Co As H Novel method for down-regulation of amyloid
JP2005505271A (ja) 2001-09-06 2005-02-24 アジェンシス， インコーポレイテッド 癌の処置および検出において有用なｓｔｅａｐ−１と名称が与えられる核酸および対応するタンパク質
MY139983A (en) * 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
WO2004000873A2 (en) * 2002-06-25 2003-12-31 City Of Hope Adjuvant-free peptide vaccine
WO2004016733A2 (en) 2002-08-16 2004-02-26 Agensys, Inc. Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
US7432351B1 (en) 2002-10-04 2008-10-07 Mayo Foundation For Medical Education And Research B7-H1 variants
TW200509968A (en) 2002-11-01 2005-03-16 Elan Pharm Inc Prevention and treatment of synucleinopathic disease
US8506959B2 (en) 2002-11-01 2013-08-13 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
JP2006508163A (ja) 2002-11-27 2006-03-09 アジェンシス， インコーポレイテッド 癌の処置および検出において有用な２４ｐ４ｃ１２と称される、核酸および対応タンパク質
EP1903056A3 (de) 2002-12-10 2008-05-07 Idm Pharma, Inc. HLA-A1, -A2, -A3, -A24, -B7 and -B44 bindende Peptide die Tumorassoziiert-Antigen Epitopen enthalten, und Zusammensetzungen davon
WO2004052930A2 (en) * 2002-12-11 2004-06-24 Pharmexa A/S Targeting single epitopes
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
JP2006516639A (ja) * 2003-02-01 2006-07-06 ニユーララブ・リミテツド 可溶性Ａ−βに対する抗体を生成させるための能動免疫
CA2515699C (en) 2003-02-10 2015-01-27 Aya Jakobovits Nucleic acid and corresponding protein named 158p1d7 useful in the treatment and detection of bladder and other cancers
CA2520768A1 (en) * 2003-03-28 2005-02-10 Idm Pharma, Inc. Methods of identifying optimal variants of peptide epitopes
DK1620456T3 (da) 2003-04-18 2014-04-22 Biotech Synergy Inc Hla-a2 tumor-associerede antigen-peptider og præparater
EP2319524B1 (de) 2003-05-30 2013-08-21 Agensys, Inc. Prostatstammzellenantigen-Varianten und Untersequenzen davon
PE20050627A1 (es) 2003-05-30 2005-08-10 Wyeth Corp Anticuerpos humanizados que reconocen el peptido beta amiloideo
US9090673B2 (en) * 2003-12-12 2015-07-28 City Of Hope Synthetic conjugate of CpG DNA and T-help/CTL peptide
DK1701968T3 (da) 2003-12-17 2015-06-22 Wyeth Llc Immunogene peptid-bærer-konjugater og fremgangsmåder til deres fremstilling
BRPI0417689A8 (pt) 2003-12-17 2017-04-25 Elan Pharm Inc Método para conjugar um imonógeno de peptídeo, composição, conjugado, composição imunogênica, método para induzir uma resposta imune em um indivíduo mamífero, e, uso do conjugado
WO2005118864A2 (en) 2004-05-28 2005-12-15 Agensys, Inc. Antibodies and related molecules that bind to psca proteins
AU2005250170A1 (en) * 2004-06-01 2005-12-15 Genimmune N.V. Peptides for inducing a CTL and/or HTL response to hepatitis C virus
EP1781326A4 (de) * 2004-06-04 2009-01-14 Pharmexa Inc Induktion einer immunantwort gegen streptokokkenpneumonie-polysacchariden
EA013752B1 (ru) 2004-08-09 2010-06-30 Элан Фармасьютикалз, Инк. Предупреждение и лечение синуклеинопатических и амилоидогенных заболеваний
SI1810026T1 (en) 2004-10-06 2018-08-31 Mayo Foundation For Medical Education And Research B7-h1 and pd-1 in treatment of renal cell carcinoma
MX2007006750A (es) 2004-12-06 2007-11-23 Univ California Metodos para mejorar la estructura y funcion de arteriolas.
AR051528A1 (es) * 2004-12-15 2007-01-17 Neuralab Ltd Anticuerpos humanizados que reconocen el peptido beta amiloideo
AR051800A1 (es) * 2004-12-15 2007-02-07 Wyeth Corp Anticuerpos a beta usados en mejorar la cognicion
US8916165B2 (en) * 2004-12-15 2014-12-23 Janssen Alzheimer Immunotherapy Humanized Aβ antibodies for use in improving cognition
KR100646313B1 (ko) 2004-12-31 2006-11-14 강원대학교산학협력단 알러지 질환 예방 및 치료용 펩티드 또는 그의 염 및 이를함유한 의약 조성물
EP2444099A1 (de) 2005-03-31 2012-04-25 Agensys, Inc. An 161P2F10B-Proteine bindende Antikörper und zugehörige Moleküle
AU2006319358B2 (en) 2005-11-30 2012-01-19 AbbVie Deutschland GmbH & Co. KG Anti-Abeta globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
KR20140087058A (ko) 2005-11-30 2014-07-08 애브비 인코포레이티드 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
ES2310072B1 (es) * 2005-12-23 2009-11-16 Proyecto De Biomedicina Cima, S.L. Nuevos peptidos determinantes antigenicos t colaboradores (/dth).
CA2674269C (en) 2006-01-03 2018-06-12 University Of Georgia Research Foundation, Inc. Three component glycolipopeptides
US20090036653A1 (en) * 2006-04-13 2009-02-05 Peptimmune, Inc. Methods for the directed expansion of epitopes for use as antibody ligands
CA2649296A1 (en) * 2006-04-13 2007-10-25 Peptimmune, Inc. Methods for designing and synthesizing directed sequence polymer compositions via the directed expansion of epitope permeability
US8784810B2 (en) * 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
DK2023952T3 (en) 2006-05-18 2015-10-19 Epimmune Inc Induction of immune responses to influenza virus using polypeptide and nucleic acid compositions
CA2653628C (en) 2006-06-01 2015-07-14 Elan Pharmaceuticals, Inc. Neuroactive fragments of app
PL2476435T3 (pl) 2006-08-11 2018-05-30 Life Sciences Research Partners Vzw Peptydy immunogenne i ich zastosowanie w zaburzeniach immunologicznych
US7807146B2 (en) 2006-10-06 2010-10-05 Bn Immunotherapeutics, Inc. Methods for treating cancer with a recombinant MVA expressing HER-2
US20090142362A1 (en) * 2006-11-06 2009-06-04 Avant Immunotherapeutics, Inc. Peptide-based vaccine compositions to endogenous cholesteryl ester transfer protein (CETP)
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US8440185B2 (en) * 2006-12-26 2013-05-14 The Johns Hopkins University Compositions and methods for the treatment of immunologic disorders
EP2124998B8 (de) 2006-12-27 2015-05-06 The Johns Hopkins University Verfahren zum nachweis von entzündungs- und autoimmunerkrankungen
US20090142342A1 (en) * 2006-12-27 2009-06-04 Johns Hopkins University B7-h4 receptor agonist compositions and methods for treating inflammation and auto-immune diseases
US7989173B2 (en) 2006-12-27 2011-08-02 The Johns Hopkins University Detection and diagnosis of inflammatory disorders
ES2546863T3 (es) 2007-02-23 2015-09-29 Prothena Biosciences Limited Prevención y tratamiento de enfermedad sinucleinopática y amiloidogénica
PL2583978T3 (pl) 2007-02-23 2016-07-29 Prothena Biosciences Ltd Co Profilaktyka i leczenie chorób synukleinopatycznych i amyloidogennych
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
EP2134176A4 (de) * 2007-03-30 2012-08-29 Brigham & Womens Hospital Verbindungen und verfahren zur verbesserung von mhc-klasse-ii-therapien
US8003097B2 (en) * 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
CN101970000A (zh) * 2007-04-18 2011-02-09 杨森阿尔茨海默氏症免疫治疗公司 脑淀粉样血管病的预防和治疗
AU2008287530A1 (en) * 2007-05-07 2009-02-19 Peptimmune, Inc. Methods for the directed expansion of epitopes for use as antibody ligands
DK2182983T3 (da) 2007-07-27 2014-07-14 Janssen Alzheimer Immunotherap Behandling af amyloidogene sygdomme med humaniserede anti-abeta antistoffer
NZ585367A (en) * 2007-10-16 2012-12-21 Peptimmune Inc Methods for designing and preparing vaccines comprising directed sequence polymer compositions via the directed expansion of epitopes
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
CN102066410B (zh) 2007-11-01 2017-01-18 梅约医学教育与研究基金会 Hla‑dr结合肽和它们的应用
US20090169549A1 (en) * 2007-12-19 2009-07-02 The Board Of Regents Of The University Of Texas System Conformational isomers of alpha-synuclein, antibodies thereto and methods of their manufacture and use
EA028356B1 (ru) 2007-12-28 2017-11-30 Протена Байосайенсиз Лимитед Лечение и профилактика амилоидоза
ES2676630T3 (es) 2008-02-14 2018-07-23 Life Sciences Research Partners Vzw Control inmunogénico de tumores y células tumorales
CA2759118A1 (en) * 2008-04-17 2009-10-22 Declion Pharmaceuticals, Inc. Design and synthesis of directed sequence polymer compositions and antibodies thereof for the treatment of protein conformational disorders
US20120039984A1 (en) 2008-07-03 2012-02-16 University Of Georgia Research Foundation, Inc. Glycopeptide and uses thereof
US20110206736A1 (en) * 2008-09-23 2011-08-25 Thomas Jefferson University Cancer Vaccines Against Mucosal Antigens and Methods of Making and Using the Same
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
US9249187B2 (en) 2009-01-28 2016-02-02 Epimmune Inc. Pan-DR binding polypeptides and uses thereof
EP2391748A4 (de) * 2009-01-28 2012-08-01 Antigen Express Inc Li-key-hybridpeptide zur modulation der immunreaktion auf influenza
CN102448491A (zh) * 2009-04-01 2012-05-09 迈阿密大学 疫苗组合物和其使用方法
WO2010135394A1 (en) 2009-05-19 2010-11-25 University Of Miami Compositions, kits and methods for in vitro antigen presentation, assessing vaccine efficacy, and assessing immunotoxicity of biologics and drugs
EP2473523A2 (de) 2009-08-31 2012-07-11 Amplimmune, Inc. Verfahren und zusammensetzungen zur hemmung von transplantatabstossung
EP3444333A1 (de) 2009-10-22 2019-02-20 Thomas Jefferson University Zellbasierte antikrebszusammensetzungen sowie verfahren zur herstellung und verwendung davon
CA2796339C (en) 2010-04-15 2020-03-31 Abbott Laboratories Amyloid-beta binding proteins
EP2575773A4 (de) 2010-05-26 2014-06-25 Selecta Biosciences Inc Synthetische nanoträgerkombinationsimpfstoffe
JP6147665B2 (ja) 2010-08-14 2017-06-14 アッヴィ・インコーポレイテッド アミロイドベータ結合タンパク質
AU2011335551B2 (en) 2010-12-02 2016-10-06 Bionor Immuno As Peptide scaffold design
BR112013017488A2 (pt) 2011-01-06 2017-08-01 Bionor Immuno As peptídeos imunogênicos multiméricos e monoméricos
JP2011201902A (ja) * 2011-05-19 2011-10-13 Wyeth Llc 可溶性Ａ−βに対する抗体を生成させるための能動免疫
WO2013019669A2 (en) 2011-07-29 2013-02-07 Selecta Biosciences, Inc. Synthetic nanocarriers that generate humoral and cytotoxic t lymphocyte (ctl) immune responses
JP2014530224A (ja) 2011-10-12 2014-11-17 アルファ−オー・ペプチドズ・アーゲーＡｌｐｈａ−Ｏ Ｐｅｐｔｉｄｅｓ Ａｇ ノロウイルス感染に対するワクチンとしての自己集合ペプチドナノパーティクル
GB201201511D0 (en) * 2012-01-30 2012-03-14 Univ Leuven Kath Modified epitopes for boosting CD4+ T-cell responses
WO2013182661A1 (en) 2012-06-06 2013-12-12 Bionor Immuno As Peptides derived from viral proteins for use as immunogens and dosage reactants
US20150283220A1 (en) 2012-10-19 2015-10-08 Bavarian Nordic, Inc. Methods and compositions for the treatment of cancer
PE20152004A1 (es) 2013-03-13 2016-02-07 Prothena Biosciences Ltd Inmunoterapia tau
US9302005B2 (en) 2013-03-14 2016-04-05 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
GB201309469D0 (en) 2013-05-28 2013-07-10 Imcyse Sa Detection of CD4+ T lymphocytes
US10272144B2 (en) 2013-07-31 2019-04-30 Bioventures, Llc Compositions for and methods of treating and preventing targeting tumor associated carbohydrate antigens
ES2714708T3 (es) 2013-10-01 2019-05-29 Mayo Found Medical Education & Res Procedimientos para el tratamiento de cáncer en pacientes con niveles elevados de Bim
EP3071974A2 (de) 2013-11-19 2016-09-28 Prothena Biosciences Limited Überwachung der immuntherapie von lewy-körperchen-krankheit aus verstopfungssymptomen
US9828436B2 (en) 2014-03-19 2017-11-28 Mackay Medical Foundation The Presbyterian Church In Taiwan Mackay Memorial Hospital Antibodies against immunogenic glycopeptides, compositions comprising the same and use thereof
EP3134104B1 (de) 2014-04-25 2018-12-26 Tria Bioscience Corp. Synthetische haptenträgerzusammensetzungen und verfahren
IL248511B (en) 2014-05-13 2022-07-01 Bavarian Nordic As Combination therapy for treating cancer with a poxvirus expressing a tumor antigen and a monoclonal antibody against tim-3
WO2015179654A1 (en) 2014-05-22 2015-11-26 Mayo Foundation For Medical Education And Research Distinguishing antagonistic and agonistic anti b7-h1 antibodies
US10517875B2 (en) 2014-07-23 2019-12-31 Mayo Foundation for Medical Engineering and Research Targeting DNA-PKcs and B7-H1 to treat cancer
GB201418433D0 (en) 2014-10-17 2014-12-03 Imcyse Sa Novel immunogenic peptides
ES2842849T3 (es) 2015-05-05 2021-07-15 Univ California Péptidos CTL H3.3 y usos de los mismos
US10441644B2 (en) 2015-05-05 2019-10-15 The Regents Of The University Of California H3.3 CTL peptides and uses thereof
US10729791B2 (en) 2015-05-18 2020-08-04 Imcyse Sa Animal models for evaluating pharmaceutical compounds
IL255722B2 (en) 2015-06-29 2024-05-01 Ose Immunotherapeutics A method for inducing an early memory response with an anticancer vaccine of short peptides
US10875923B2 (en) 2015-10-30 2020-12-29 Mayo Foundation For Medical Education And Research Antibodies to B7-H1
CA3018748A1 (en) 2016-03-31 2017-10-05 Neon Therapeutics, Inc. Neoantigens and methods of their use
WO2017191559A1 (en) 2016-05-02 2017-11-09 Prothena Biosciences Limited Tau immunotherapy
EA201892233A1 (ru) 2016-05-02 2019-07-31 Зе Скриппс Рисёрч Инститьют Композиции и способы, связанные с иммуногенами вич-1
US10906964B2 (en) 2016-05-02 2021-02-02 Prothena Biosciences Limited Antibodies recognizing tau
UA124148C2 (uk) 2016-05-02 2021-07-28 Протена Біосайенсіс Лімітед Антитіла, що розпізнають тау
CA3058807A1 (en) 2017-04-03 2018-10-11 Neon Therapeutics, Inc. Protein antigens and uses thereof
MX2019013045A (es) 2017-05-02 2020-02-12 Prothena Biosciences Ltd Anticuerpos que reconocen tau.
PE20191842A1 (es) 2017-05-08 2019-12-31 Gritstone Oncology Inc Vectores de neoantigeno de alfavirus
WO2018213803A1 (en) 2017-05-19 2018-11-22 Neon Therapeutics, Inc. Immunogenic neoantigen identification
US10988754B2 (en) 2017-07-04 2021-04-27 Cure Vac AG Nucleic acid molecules
US10780178B2 (en) 2017-11-01 2020-09-22 The Scripps Research Institute Scaffolded HIV-1 vaccine immunogens
BR112020010656A2 (pt) 2017-11-27 2020-11-10 Ose Immunotherapeutics tratamento aprimorado de câncer
US20220153871A1 (en) 2018-01-04 2022-05-19 Iconic Therapeutics, Inc. Anti-Tissue Factor Antibodies, Antibody-Drug Conjugates, and Related Methods
CN109748952B (zh) 2018-05-02 2020-09-15 中国药科大学 辅助性表位肽及其应用
WO2019241483A1 (en) 2018-06-13 2019-12-19 The Scripps Research Institute Nanoparticle vaccines with novel structural components
IL281988B2 (en) 2018-10-05 2025-03-01 Bavarian Nordic As Combination therapy for treating cancer with an intravenous administration of a recombinant mva and an immune checkpoint antagonist or agonist
EP3873500A4 (de) 2018-10-31 2023-01-11 Mayo Foundation for Medical Education and Research Verfahren und materialien zur behandlung von krebs
EP3873540A4 (de) 2018-10-31 2022-07-27 Mayo Foundation for Medical Education and Research Verfahren und materialien zur behandlung von krebs
MX2021005560A (es) 2018-11-20 2021-06-23 Bavarian Nordic As Terapia para el tratamiento del cancer con administracion intratumoral y/o intravenosa de un virus vaccinia ankara (mva) recombinante que codifica ligando 4-1bbl (cd137l) y/o ligando del cumulo o grupo de diferenciacion 40 (cd40l).
TW202039534A (zh) 2018-12-14 2020-11-01 美商美國禮來大藥廠 KRAS變體mRNA分子
CA3126544A1 (en) 2019-01-12 2020-07-16 The Methodist Hospital Self-assembled peptide nanoparticle and use thereof
CN113544149B (zh) 2019-03-03 2024-11-15 普罗塞纳生物科学有限公司 识别tau的抗体
TW202523847A (zh) 2019-05-30 2025-06-16 美商磨石生物公司 經修飾之腺病毒
KR20220106775A (ko) 2019-11-20 2022-07-29 버베리안 노딕 에이/에스 암 치료를 위한 종양내 및/또는 정맥내 투여를 위한 재조합 mva 바이러스
EP4069722A1 (de) 2019-12-02 2022-10-12 Regeneron Pharmaceuticals, Inc. Peptid-mhc-ii-proteinkonstrukte und deren verwendungen
US20230181721A1 (en) 2020-05-11 2023-06-15 Ose Immunotherapeutics Vaccine against sars-cov virus
EP4153210A4 (de) 2020-05-19 2024-11-13 Othair Prothena Limited Multiepitop-impfstoff zur behandlung von morbus alzheimer
CN116249717A (zh) 2020-06-24 2023-06-09 普罗塞纳生物科学有限公司 识别分拣蛋白的抗体
CN116438308A (zh) 2020-08-06 2023-07-14 磨石生物公司 多表位疫苗盒
JP2023536995A (ja) 2020-08-07 2023-08-30 オター プロシーナ リミテッド アルツハイマー病を処置するためのマルチエピトープワクチン
WO2022268916A2 (en) 2021-06-23 2022-12-29 Ose Immunotherapeutics Pan-coronavirus peptide vaccine
WO2023118508A1 (en) 2021-12-23 2023-06-29 Bavarian Nordic A/S Recombinant mva viruses for intraperitoneal administration for treating cancer
CN119256003A (zh) 2022-04-14 2025-01-03 儿童医院 基于pfcsp的免疫原及其相关组合物和方法
TW202530252A (zh) 2023-09-15 2025-08-01 愛爾蘭商普羅希那生物科學有限公司 降低抗體免疫原性及改良抗體穩定性之組成物及方法
AR133120A1 (es) 2023-09-22 2025-08-27 Regeneron Pharma Métodos para obtener moléculas de anticuerpos que se unen a una interfaz péptido-mhc
WO2025093541A1 (en) 2023-10-31 2025-05-08 Ose Immunotherapeutics Combination of interleukin 7 and tumour associated antigen vaccine

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5785973A (en) 1988-02-01 1998-07-28 Praxis Biologics, Inc. Synthetic peptides representing a T-cell epitope as a carrier molecule for conjugate vaccines
GB8812214D0 (en) * 1988-05-24 1988-06-29 Hoffmann La Roche Use of peptide from circumsporozoite protein of p falciparum as universally recognized t-cell epitope
IT1237764B (it) * 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
US5336758A (en) * 1990-03-09 1994-08-09 The United States Of America As Represented By The Department Of Health And Human Services Peptides stimulating cytotoxic T cells immune to HIV RT
AU8305491A (en) * 1990-08-01 1992-03-02 Cytel Corporation Novel immunosuppressant peptides
US5679640A (en) 1991-02-12 1997-10-21 Cytel Corporation Immunosuppressant peptides
DE69231621T2 (de) * 1991-08-26 2001-05-31 Epimmune, Inc. Hepatitis-B-Virus-Epitope mit HLA-reduzierte CTL-Respons
AU2468392A (en) * 1991-08-29 1993-04-05 Cytel Corporation Novel immunosuppressants
JP3908271B2 (ja) 1993-03-05 2007-04-25 エピミューン，インコーポレイティド Ｈｌａ−ａ２．１結合ペプチドおよびそれらの使用
ES2318848T3 (es) 1993-09-14 2009-05-01 Pharmexa Inc. Peptidos que se unen a pan dr para potenciar la respuesta inmunitaria.
AU4078599A (en) * 1998-05-13 1999-11-29 Epimmune, Inc. Expression vectors for stimulating an immune response and methods of using the same

Also Published As

Publication number Publication date
AU7873694A (en) 1995-04-03
JP3926839B2 (ja) 2007-06-06
JPH09505559A (ja) 1997-06-03
US5736142A (en) 1998-04-07
DE69435171D1 (de) 2009-01-08
WO1995007707A1 (en) 1995-03-23
EP0735893A1 (de) 1996-10-09
ES2318848T3 (es) 2009-05-01
EP0735893B1 (de) 2008-11-26
EP0735893A4 (de) 1998-02-04
AU698962B2 (en) 1998-11-12
DK0735893T3 (da) 2009-03-09
CN1135181A (zh) 1996-11-06
US7202351B1 (en) 2007-04-10
PT735893E (pt) 2009-03-06

Similar Documents

Publication Publication Date Title
ATE415173T1 (de) Pan dr-bindeproteinen zur erhöhung der immunantwort
DE69326064D1 (de) Peptide des menschlichen Proteins P53 zum Gebrauch in menschlichen-zytotoxischen-T-Zell-Antwort-induzierenden Kompositionen sowie menschliche P53-Protein-spezifische T-Lymphocyten
ATE242633T1 (de) Dialkylfumarate zur behandlung von autoimmunerkrankungen
BR9907995A (pt) Métodos imunológicos para modular miostatina em sujeitos vertebrados
WO1998026747A3 (en) Superantigen based methods and compositions for treatment of diseases
DK0503648T3 (da) CD2-bindingsdomæne af lymfocytfunktion-associeret antigen 3
DE3889536D1 (de) Behandlung von krebs mit somatostatin und mit analogen davon.
RU94046424A (ru) Способ разделения форм днказы, днказа человека, фармацевтическая композиция, способ хранения днказы, способ лечения
DK0914144T3 (da) Terapeutiske anvendelser af BPI-protein-produkter til human meningokokæmi
ATE177757T1 (de) Verbesserte immunogene zusammensetzung gegen mensliches gastrin 17
DE69726426D1 (de) Unterdrückung von immunantwort durch hemmung von cathepsin s
DE69430868D1 (de) Verfahren und zubereitungen zur verzoegerung oder vorbeugung von autoimmun krankheiten
BR9306345A (pt) Métodos para suprimir a habilidade de células-t de um mamífero de proliferar e para suprimir resposta imune composições para uso na supressão da capacidade de células-t de proliferarem e na supressão de resposta imune
DE69719754D1 (de) Therapeutische verwendungen von bpi-protein produkten bei menschen mit durch trauma verursachter blutung
KR980002066A (ko) 변이형 인간 성장호르몬 및 그의 용도
IL92629A0 (en) Direct binding of t-cell epitopes to mhc gene products on intact living antigen presenting cells and the use thereof for identifying epitopes causing autoimmune diseases and pharmaceutical compositions for treating such diseases
WO1993019178A3 (en) Peptides useful for inducing tolerance
WO1996018646A3 (en) Heat shock protein peptides and methods for modulating autoimmune central nervous system disease
RU99107658A (ru) Применение белков в качестве агентов против аутоиммунных заболеваний
CA2157500A1 (en) Lo-cd2a antibody and uses thereof for inhibiting t-cell activation and proliferation
WO1996020950A3 (en) Compositions and methods for treating rheumatoid arthritis
ATE359296T1 (de) Pharmazeutische peptide formulierungen zur behandlung von staubmilben allergie
DK1039931T3 (da) Multivalente rekombinante antistoffer til at behandle HRV infektioner
IL106065A0 (en) Synthetic peptides for the treatment of myasthenia gravis and compositions comprising them
DE68914397D1 (de) Menschliches Lymphotoxin.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0735893

Country of ref document: EP